AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)